Journal of Medicinal Chemistry
Article
residue was purified by column chromatography (EtOAc:heptane: 1:3)
affording the product. When possible, the product was recrystallized
from EtOAc/heptane.
compounds 3, 7, 8, 15, 19, 21, 22, 26, 28−35, and 38−44. This
material is available free of charge via the Internet at http://
(2S,6′R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1′-(2′-(naphthalen-1-ylmethoxy)-6′-methylcyclohex-2′-
ene-4′-one-4′-oxime) 38. To a solution of 26 (0.08 mmol, 1.0
equiv) in EtOH (2 mL) and DMSO (1 mL) was added hydroxylamine
hydrochloride (0.30 mmol, 3.5 equiv) and sodium acetate (0.37 mmol,
4.3 equiv). The mixture was stirred at 75 °C for 18 h, allowed to reach
20 °C, and diluted with EtOAc (5 mL). The mixture was washed with
brine (3 × 4 mL). The organic phase was dried (MgSO4) and
concentrated. The crude mixture was purified by column chromatog-
raphy (EtOAc:heptane 1:1) to afford 38 (40 mg, 96%) as a yellow oil.
Rf values (EtOAc/heptane, 5:1), 0.60 and 0.51. IR (neat, cm−1): 1704,
AUTHOR INFORMATION
Corresponding Author
■
ACKNOWLEDGMENTS
■
We thank Anja Irsigler, Christine Immel, and Sigrid Heil for
cytotoxicity assay testing. We thank Brian Dideriksen for
assistance with stability studies. We thank the Danish Research
Council (reference no. 274-07-0561), the Deutsche Krebshilfe
(grant no. 107739), and the Karen Krieger Foundation for
financial support.
1
1613, 1590. H NMR (500 MHz, CDCl3): δ 7.82−7.73 (3H, m),
7.50−7.42 (2H, m), 7.37−7.32 (2H, m), 6.54 (0.4H, s), 5.99 (0.6H, s),
5.96 (0.4H, s), 5.84 (0.6H, s), 5.31 (0.4H, d, J = 12.0 Hz), 5.29 (0.6H,
d, J = 12.0 Hz), 5.26 (0.4H, d, J = 11.9 Hz), 5.23 (0.6H, d, J = 11.9
Hz), 3.95 (1.8H, s), 3.93 (1.2H, s), 3.91 (1.8H, s), 3.90 (1.2H, s), 3.15
(0.6 H, dd, J = 16.8, 4.9 Hz), 3.06 (0.4 H, dd, J = 15.0, 13.3 Hz), 2.75
(0.6 H, dd, J = 16.8, 13.1 Hz), 2.70−2.57 (1 H, m), 2.44 (0.4 H, dd,
J = 15.0, 4.1 Hz), 0.98 (1.8H, d, J = 6.7 Hz), 0.98 (1.2H, d, 6.8 Hz).
13C NMR (75 MHz, CDCl3): δ 194.0 (0.5C, s), 193.9 (0.5C, s), 169.3
ABBREVIATIONS USED
■
CSA, camphor sulfonic acid; DBU, 1,8-diazabicyclo[5.4.0]-
undec-7-ene; MAP, microtubule-associated protein; PBS,
phosphate-buffered saline; SAR, structure−activity relationship
(0.5C, s), 164.0 (0.5C, s), 160.0 (0.5C, s), 157.3 (0.5C, s), 157.3
(0.5C, s), 157.3 (0.5C, s), 155.0 (0.5C, s), 151.8 (0.5C, s), 133.3
(0.5C, s), 131.2 (0.5C, s), 131.1 (0.5C, s), 130.8 (0.5C, s), 130.6
(0.5C, s), 128.9 (0.5C, s), 128.9 (0.5C, s), 128.8 (0.5C, s), 128.3
(0.5C, s), 128.2 (0.5C, s), 128.1 (0.5C, s), 126.3 (0.5C, s), 126.3
(0.5C, s), 126.2 (0.5C, s), 126.0 (0.5C, s), 125.7 (0.5C, s), 125.6
(0.5C, s), 125.2 (0.5C, s), 125.0 (0.5C, s), 124.9 (0.5C, s), 123.6
(0.5C, s), 123.5 (0.5C, s), 105.6 (0.5C, s), 105.5 (0.5C, s), 100.5
(0.5C, s), 96.9 (0.5C, s), 96.8 (0.5C, s), 93.9 (0.5C, s), 91.5 (0.5C, s),
91.4 (0.5C, s), 89.0 (0.5C, s), 89.0 (0.5C, s), 69.4 (0.5C, s), 69.0
(0.5C, s), 56.7 (1 C, s), 56.1 (0.5C, s), 56.1 (0.5C, s), 36.4 (0.5C, s),
35.2 (0.5C, s), 30.9 (0.5C, s), 25.5 (0.5C, s), 14.4 (0.5 C, s), 14.3
(0.5 C, s); [α]20D = +112° (c = 1.0 in CDCl3). HRMS (ESI+) calcd for
M + H [C27H25ClNO6]+ 494.1370, found 494.1371.
REFERENCES
■
(1) Oxford, A. E.; Raistrick, H.; Simonart, P. Studies in the
biochemistry of micro-organisms. LX. Griseofulvin, C17H17O6Cl, a
metabolic product of Penicillium griseo-fulvum Dierckx. Biochem. J.
1939, 33, 240−248.
(2) Gentles, J. C. Experimental Ringworm in Guinea PigsOral
Treatment with Griseofulvin. Nature 1958, 182, 476−477.
(3) Williams, D. I.; Marten, R. H.; Sarkany, I. Oral Treatment of
Ringworm with Griseofulvin. Lancet 1958, 2, 1212−1213.
(4) Alles, R.; Bekker, D.; Bonni, Z.; Khirsh, S.; Kal, B. O.; Kelle, E. U.
L. R.; Majer, F. K.; Shtjutts, A.; Uill, J. A. Terbinafine Solid Medicinal
Formulation for Oral Administration. Russian Patent RU2298402,
2007.
(5) Terbinafine. FDA: Washington, DC, 11/11/2011; http://www.
(6) Gupta, A. K.; Summerbell, R. C. Tinea capitis. Med. Mycol. 2000,
38, 255−287.
(7) Seebacher, C.; Abeck, D.; Brasch, J.; Cornely, O.; Daeschlein, G.;
Effendy, I.; Ginter-Hanselmayer, G.; Haake, N.; Hamm, G.; Hipler, C.;
Hof, H.; Korting, H. C.; Kramer, A.; Mayser, P.; Ruhnke, M.; Schlacke,
K. H.; Tietz, H. J. Tinea capitis: ringworm of the scalp. Mycoses 2007,
50, 218−226.
The analogue 35 was synthesized according to the general pro-
cedure for 2′ enol ethers with the starting material being 15 instead
of 16.
(2S,6′R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-
1′-(4′-(3-methoxybenzyl)oxy-6′-methyl-cyclohex-3′-en-2′-
one] 35. Yield: 83 mg (32%) (white crystals); Rf value (EtOAc/
heptane, 5:1): 0.65; mp 173−175 °C. IR (neat, cm−1): 1691, 1653,
1
1605, 1584. H NMR (CDCl3, 300 MHz): δ 7.37−7.27 (1H, m),
7.02−6.84 (3H, m), 6.09 (1H, s), 5.54 (1H, d, J = 1.0 Hz), 5.01−4.85
(2H, m), 4.01 (3H, s), 3.93 (3H, s), 3.84 (3H, s), 3.26 (1H, ddd, J =
17.5, 11.9, 1.0 Hz), 2.96−2.80 (1H, m), 2.54 (1H, dd, J = 17.5,
5.6 Hz), 1.03 (3H, d, J = 6.6 Hz). 13C NMR (CDCl3, 50 MHz): δ
191.7, 188.8, 177.7, 169.7, 164.5, 159.9, 157.7, 136.0, 129.7, 120.0,
114.2, 113.2, 105.1, 100.7, 97.3, 95.1, 89.5, 71.0, 57.0, 56.2, 55.3, 35.2,
(8) Sobue, S.; Sekiguchi, K.; Nabeshima, T. Intracutaneous
distributions of fluconazole, itraconazole, and griseofulvin in guinea
pigs and binding to human stratum corneum. Antimicrob. Agents
Chemother. 2004, 48, 216−223.
33.2 14.5; [α]20 = +179° (c = 0.6 in CCl3). HRMS (ESI+) calcd for
D
[M + H]+ [C24H24ClO7]+ 459,1211, found 459.1216.
(9) Chaudhuri, A. R.; Luduena, R. F. Griseofulvin: Interaction With
̃
General Procedure for the Synthesis of Enol Ethers by
Solvolysis (42 and 43). CSA (0.1 mmol, 0.1 equiv) was added to a
solution of griseofulvic acid (0.6 mmol, 1 equiv) in the appropriate
alcohol (6 mL, 0.1 M). The mixture was stirred at 100 °C for 6 h and
then cooled to 20 °C. EtOAc (20 mL) was added to the solution, and
the mixture was washed with satd aq NaH2PO4 (20 mL) and water
(20 mL). The combined aqueous phases were extracted with EtOAc
(3 × 20 mL), and the combined organic phases were dried (MgSO4)
and concentrated. The residue was purified by column chromatog-
raphy (toluene:CH2Cl2:EtOAc 7:7:1) to afford the desired products.
When possible, the products were recrystallized from EtOAc/heptane.
Normal and Subtilisin-Treated Tubulin. Drug Dev. Res. 2001, 53,
44−49.
(10) Wehland, J.; Herzog, W.; Weber, K. Interaction of Griseofulvin
with Microtubules, Microtubule Protein and Tubulin. J. Mol. Biol.
1977, 111, 329−342.
(11) Crosse, R.; Rhodes, A.; Mcwillia, R. Some Relations between
Chemical Structure and Antifungal Effects of Griseofulvin Analogues.
J. Gen. Microbiol. 1964, 34, 51−65.
(12) Crowdy, S. H.; Grove, J. F.; McCloskey, P. Translocation of
Antibiotics in Higher Plants 0.4. Systemic Fungicidal Activity and
Chemical Structure in Griseofulvin Relatives. Biochem. J. 1959, 72,
241−249.
(13) Delgado, L.; De Croos, P. Z.; Lu, M. C. H.; Currie, B. L.
Structure Modification and Biological Activity of Some Griseofulvin
Derivatives. Kaohsiung J. Med. Sci. 1992, 8, 632−639.
(14) Yamato, M.; Yoshida, H.; Ikezawa, K.; Kohashi, Y. Synthesis of a
Griseofulvin Analogue. Chem. Pharm. Bull. 1986, 34, 71−76.
ASSOCIATED CONTENT
■
S
* Supporting Information
Full experimental data for compounds 3, 7, 8, 19, 21, 22, 26,
28−34, and 39−44, as well as copies of NMR spectra for
659
dx.doi.org/10.1021/jm200835c | J. Med. Chem. 2012, 55, 652−660